Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched in oligodendrocytes (62 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
Knock down and overexpress TMED7 in oligodendrocytes; measure LRRK2 kinase activity (pT73-Rab10) and lysosome position and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- LRRK2 kinase activity (pT73-Rab10) and lysosome position
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves LRRK2 kinase activity (pT73-Rab10) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of TMED7 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: LRRK2 kinase activity (pT73-Rab10) and lysosome position; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- TMED7 in dopamine neurons, braak-0.31 (p 0.416) → +0.09 (p 0.815)receipt 16334
- TMED7 in oligodendrocytes, braak+0.00 (p 1.000) → -0.04 (p 0.924)receipt 16333
Swarm cases
receipt 16334: TMED7 in dopamine neurons, braak
- power
- full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.969, n 18). could be the mix.
- skeptic
- leave-one-out range -0.11 to +0.13, sign flips 8; without severely affected donors -0.00 (p 0.990, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMED7 in dopamine neurons.
case closed: nothing better to follow up.
receipt 16333: TMED7 in oligodendrocytes, braak
- power
- full sample +0.10 (p 0.690, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.544, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.07 (p 0.787, n 18). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.21, sign flips 1; without severely affected donors +0.10 (p 0.690, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TMED7 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts